Skip to main content

Table 3 Summary of AmbulatoryBlood pressure monitoring

From: Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

Time Reading (Adjusted Mean Change from Baseline inmmHg; p-value) RE 500 mg + Metformin(N = 14) RE 750 mg + Metformin(N = 14)
24 h Systolic −2.8; p = 0.303 −4.0; p = 0.131
Diastolic −2.0; p = 0.256 −3.3; p = 0.062
Daytime Systolic −3.4; p = 0.291 −2.4; p = 0.441
Diastolic −1.8; p = 0.461 −1.3; p = 0.586
Nighttime Systolic −8.4; p = 0.020 −7.1; p = 0.047
Diastolic −6.5; p = 0.006 −4.8; p = 0.043
  1. BP Blood pressure, RE Remogliflozin Etabonate
  2. The changes were ANCOVA adjusted mean change from baseline to Day 13 vs. Placebo